Specimen | Jotup

iSpecimen Launches Enhanced Custom Collection Service

Retrieved on:

Thursday, July 29, 2021

LEXINGTON,Mass., July 29, 2021 /PRNewswire/ -- iSpecimen Inc. (Nasdaq: ISPC), an online marketplace for human biospecimens ("iSpecimen" or the "Company"), today announced that it has enhanced its custom biofluids collection service to offer life sciences organizations faster delivery of urgently needed research samples.

Key Points:

LEXINGTON,Mass., July 29, 2021 /PRNewswire/ -- iSpecimen Inc. (Nasdaq: ISPC), an online marketplace for human biospecimens ("iSpecimen" or the "Company"), today announced that it has enhanced its custom biofluids collection service to offer life sciences organizations faster delivery of urgently needed research samples.
iSpecimen's Enhanced Custom Collection Service , originally intended to compensate for biospecimen collection challenges encountered during the height of the COVID-19 pandemic, was established as a way to supplement human biospecimens provided by the Company's vast network of contracted global suppliers, particularly during time-sensitive situations.
The enhanced service entails direct blood draws, saliva collection, and other forms of biofluid sample collections by qualified clinicians at iSpecimen headquarters.
Our Enhanced Custom Collection Service extends our ongoing mission of streamlining biospecimen procurement to advance medical research."

Q2 Solutions and Tasso Collaborate to Provide Unique Solutions for Patients to Accelerate Adoption of Decentralized Clinical Trials

Retrieved on:

Tuesday, June 8, 2021

Tasso is now poised to accelerate this paradigm shift in patient care through our clinical-grade and convenient blood collection experience.

Key Points:

Tasso is now poised to accelerate this paradigm shift in patient care through our clinical-grade and convenient blood collection experience.
The devices are currently in use by leading pharmaceutical companies across multiple clinical trials for their research and development efforts.
We are delighted to collaborate with Tasso on this innovative, patient-centric approach to blood collection for decentralized clinical trials, said Brian ODwyer, CEO of Q2 Solutions.
Q2 Solutions is a leading global clinical trial laboratory services organization providing comprehensive testing, project management, supply chain, biorepository, biospecimen and consent tracking solutions.

Bacterial & Viral Specimen Collection Market Size Worth $38.8 Billion By 2027: Grand View Research, Inc.

Retrieved on:

Wednesday, November 11, 2020

Vaccine-preventable diseases, Healthcare-associated infections, Health, Centers for Disease Control and Prevention, Druid Hills, Georgia, United States Public Health Service, Tuberculosis, Specimen, Medical specialties

SAN FRANCISCO, Nov. 11, 2020 /PRNewswire/ --The global bacterial and viral specimen collection market size is expected to reach USD 38.8 billion by 2027, expanding at a CAGR of 14.0%, according to a new report by Grand View Research, Inc.

Key Points:

SAN FRANCISCO, Nov. 11, 2020 /PRNewswire/ --The global bacterial and viral specimen collection market size is expected to reach USD 38.8 billion by 2027, expanding at a CAGR of 14.0%, according to a new report by Grand View Research, Inc.
This is increasing the demand for bacterial and viral specimen collecting products, thereby driving the market revenue.
As per the Centers for Disease Control and Prevention (CDC), there were around 8,920 new Tuberculosis (TB) cases in the U.S.
Grand View Research has segmented the global bacterial and viral specimen collection market on the basis of product, application, end-use, and region:
Bacterial & Viral Specimen Collection Product Outlook (Revenue, USD Million, 2016 - 2027)

Bacterial & Viral Specimen Collection Market Size Worth $38.8 Billion By 2027: Grand View Research, Inc.

Retrieved on:

Wednesday, November 11, 2020

SAN FRANCISCO, Nov. 11, 2020 /PRNewswire/ --The global bacterial and viral specimen collection market size is expected to reach USD 38.8 billion by 2027, expanding at a CAGR of 14.0%, according to a new report by Grand View Research, Inc.

Key Points:

SAN FRANCISCO, Nov. 11, 2020 /PRNewswire/ --The global bacterial and viral specimen collection market size is expected to reach USD 38.8 billion by 2027, expanding at a CAGR of 14.0%, according to a new report by Grand View Research, Inc.
This is increasing the demand for bacterial and viral specimen collecting products, thereby driving the market revenue.
As per the Centers for Disease Control and Prevention (CDC), there were around 8,920 new Tuberculosis (TB) cases in the U.S.
Grand View Research has segmented the global bacterial and viral specimen collection market on the basis of product, application, end-use, and region:
Bacterial & Viral Specimen Collection Product Outlook (Revenue, USD Million, 2016 - 2027)

Trans-Hit Biomarkers Announces Today a Partnership With Nexelis, Supporting Sample Procurement Activities for a Number of Strategic Projects Including COVID-19 Vaccines and Immuno-oncology Development Initiatives.

Retrieved on:

Thursday, October 22, 2020

Under the terms of the agreement, THB will manage Nexelis biospecimen procurement activities, consolidating Nexelis current sourcing channels with those of THB spanning over 20 countries worldwide.

Key Points:

Under the terms of the agreement, THB will manage Nexelis biospecimen procurement activities, consolidating Nexelis current sourcing channels with those of THB spanning over 20 countries worldwide.
Benoit Bouche, Nexelis Chief Executive Officer said: Fast access to quality samples is essential for turnaround and lead time purposes, and is a clear bottleneck in a number of immunology projects.
On behalf of Trans-Hit Bio and our entire team, we look forward to working closely with Nexelis, and managing their biospecimen procurement activities.
THB manages the entire biospecimen acquisition process, from the initial sample request, to the moment the samples are delivered, and beyond.

Discovery Life Sciences Expands Immunomonitoring Services To Accelerate Development Of New Cell Therapies

Retrieved on:

Tuesday, March 10, 2020

Branches of biology, Medical specialties, Medicine, Anatomical pathology, Histology, Immunohistochemistry, Pathology, Specimen

HUNTSVILLE, Ala., March 10, 2020 /PRNewswire/ -- Discovery Life Sciences(Discovery), a global leader in biospecimen solutions, genomic, cell, and immunohistochemical (IHC) services, today announced the significant expansion of its cell biology and immunology services laboratory, specifically to accelerate discovery, preclinical, and clinical development of new cell therapies and immunotherapeutics.

Key Points:

HUNTSVILLE, Ala., March 10, 2020 /PRNewswire/ -- Discovery Life Sciences(Discovery), a global leader in biospecimen solutions, genomic, cell, and immunohistochemical (IHC) services, today announced the significant expansion of its cell biology and immunology services laboratory, specifically to accelerate discovery, preclinical, and clinical development of new cell therapies and immunotherapeutics.
Discovery's combination of expert, consultative immunomonitoring services and industry-leading biospecimen solutions minimizes biospecimen-handling artifacts and significantly shortens timelines.
"The next generation of cell therapies and immunotherapies demand the application of scientific innovation and quality to advance their development to reach the patient's bedside quickly.
Discovery Life Sciences is the global market leader in biospecimen analysis, procurement, distribution, and scientific services for the pharmaceutical, biotechnology, and diagnostics industries.

Discovery Life Sciences Expands Immunomonitoring Services To Accelerate Development Of New Cell Therapies

Retrieved on:

Tuesday, March 10, 2020

Branches of biology, Medical specialties, Medicine, Anatomical pathology, Histology, Immunohistochemistry, Pathology, Specimen

HUNTSVILLE, Alabama, March 10, 2020 /PRNewswire/ -- Discovery Life Sciences(Discovery), a global leader in biospecimen solutions, genomic, cell, and immunohistochemical (IHC) services, today announced the significant expansion of its cell biology and immunology services laboratory, specifically to accelerate discovery, preclinical, and clinical development of new cell therapies and immunotherapeutics.

Key Points:

HUNTSVILLE, Alabama, March 10, 2020 /PRNewswire/ -- Discovery Life Sciences(Discovery), a global leader in biospecimen solutions, genomic, cell, and immunohistochemical (IHC) services, today announced the significant expansion of its cell biology and immunology services laboratory, specifically to accelerate discovery, preclinical, and clinical development of new cell therapies and immunotherapeutics.
Discovery's combination of expert, consultative immunomonitoring services and industry-leading biospecimen solutions minimizes biospecimen-handling artifacts and significantly shortens timelines.
"The next generation of cell therapies and immunotherapies demand the application of scientific innovation and quality to advance their development to reach the patient's bedside quickly.
Discovery Life Sciences is the global market leader in biospecimen analysis, procurement, distribution, and scientific services for the pharmaceutical, biotechnology, and diagnostics industries.

Global Automated Blood Tube Labeler and Specimen Transport Box Market 2020-2024 | Evolving Opportunities with Avantor Inc. and Greiner AG | Technavio

Retrieved on:

Friday, December 13, 2019

Packaging, Medical Supplies, Medical devices, Health, Hospitals, Manufacturing, London Underground, Subterranean London, Specimen, London, Transport in England

Technavio has been monitoring the global automated blood tube labeler and specimen transport box market, and the market is poised to grow by USD 94.57 million during 2020-2024 at a CAGR of over 7% during the forecast period.

Key Points:

Technavio has been monitoring the global automated blood tube labeler and specimen transport box market, and the market is poised to grow by USD 94.57 million during 2020-2024 at a CAGR of over 7% during the forecast period.
View the full release here: https://www.businesswire.com/news/home/20191213005437/en/
Technavio has announced its latest market research report titled global automated blood tube labeler and specimen transport box market 2020-2024.
(Graphic: Business Wire)
Read the 143-page research report with TOC on "Automated Blood Tube Labeler and Specimen Transport Box Market Analysis Report by Geography (Asia, Europe, North America, and ROW), by Product (Automated blood tube labeler and Specimen transport box), and Segment Forecasts, 2020-2024".
The automated blood tube labelers eliminate the efforts of writing, prevent the wrinkling of labels, and improve the readability of information on the labels.

Precision For Medicine Launches Biospecimen Solutions Offering With Acquisition Of ProMedDx And GLAS

Retrieved on:

Thursday, August 1, 2019

Biobanks, Biological specimen, Precision medicine, Specimen

BETHESDA, Md., Aug. 1, 2019 /PRNewswire/ -- Precision for Medicine, part of Precision Medicine Group, announced it has acquired leading biospecimen providers ProMedDx and GLAS, significantly expanding its capabilities and expertise in the biospecimen solutions space.

Key Points:

BETHESDA, Md., Aug. 1, 2019 /PRNewswire/ -- Precision for Medicine, part of Precision Medicine Group, announced it has acquired leading biospecimen providers ProMedDx and GLAS, significantly expanding its capabilities and expertise in the biospecimen solutions space.
The addition of ProMedDx and GLAS establishes an unrivaled biospecimen solutions platform within Precision, which operates one of the largest biorepositories in the world.
ProMedDx is known throughout the diagnostics industry for its high-quality biofluid specimens; GLAS is a leader in tissue-based samples.
Precision for Medicine is part of Precision Medicine Group, with nearly 2,000 employees in 34 locations in the United States, Canada, and Europe.

StemExpress Announces New Distribution Partnerships

Retrieved on:

Wednesday, April 24, 2019

Stem cells, Health, Biotechnology, Cardiology, Genetics, Pharmaceutical, Research, Science, Specimen, Biological specimen, Folsom

To continue meeting the needs of clients around the world, StemExpress announces the expansion of its existing distribution network in the Asia Pacific region, adding to their current partnerships with companies in North America, Europe, and North Africa.

Key Points:

To continue meeting the needs of clients around the world, StemExpress announces the expansion of its existing distribution network in the Asia Pacific region, adding to their current partnerships with companies in North America, Europe, and North Africa.
StemExpress now includes distribution partnerships with ATCG Limited (Hong Kong), Kim & Friends, Inc. (Korea), BIOTOOLS, Co. (Taiwan), Axil Scientific Pte Ltd (Singapore) and Custom Science (Australia).
Headquartered in Folsom, CA, StemExpress is the leading global Biospecimen provider of human primary cells and blood products.
StemExpress has a reliable and streamlined process starting with donor recruitment to shipping the final product guaranteeing every sample has the highest purity, viability, and quality.